Brief: Acumen’s ACU193 Granted FDA Fast Track Designation For Alzheimer's Disease

Acumen Pharmaceuticals

24/10/2022 13:10

Oct 24 (Reuters) - Acumen Pharmaceuticals Inc  ABOS.O :
    * ACUMEN’S ACU193, AN ANTI-AMYLOID BETA OLIGOMER ANTIBODY,
GRANTED
FDA FAST TRACK DESIGNATION FOR ALZHEIMER'S DISEASE

Source text for Eikon:  ID:nGNX4xbjJz 
Further company coverage:  ABOS.O 
 ((Reuters.Briefs@thomsonreuters.com;))